GHRP-2

The GHRP-2 evidence base cited here is 7 sources — 3 clinical, 2 preclinical, 1 review. Its strongest evidence is human — 3 clinical studies, most recently 2007 ("A Simple Diagnostic Test Using GH-Releasing Peptide-2 in Adult GH Defici…"). Regulatory status: Not FDA-approved.

• GHRP-2 (pralmorelin/KP-102) is approximately 10-fold more potent than GHRP-6 in stimulating GH secretion, with pharmacological studies (Doi et al., 2004) demonstrating superior resistance to somatostatin suppression compared to GHRH — allowing robust GH release even in states of elevated somatostatin tone.
• In a controlled study in healthy men (Laferrère et al., JCEM 2005), subcutaneous GHRP-2 infusion increased food intake by 35.9% above saline control, confirming its orexigenic activity via ghrelin receptor activation — a property that distinguishes it from more selective GH secretagogues and relevant for cachexia applications.
• A large Japanese Phase 2/3 diagnostic validation study (Chihara et al., 2007) established that IV GHRP-2 100 µg is a reliable provocative test for adult GHD, with a peak GH cut-off of 15 µg/L achieving high sensitivity and specificity — it subsequently gained approval as a GH secretion test agent in Japan.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.